During maintenance therapy for childhood ALL, there was a general increase in DNA-incorporated thioguanine nucleotides (DNA-TGN), and this increase was associated with a lower frequency of disease relapse.
Acute Lymphoblastic Leukemia
Presentation with musculoskeletal manifestations as the only symptom in pediatric B-cell acute lymphoblastic leukemia was significantly associated with diagnostic delay. However, this delay did not affect patient prognosis.
The use of minimal residual disease provided a more objective measure of induction failure in patients with pediatric acute lymphoblastic leukemia than did morphology.
In this article we discuss the challenges and new advances in adult ALL, as well as our approach to the treatment of these patients.
Among pediatric acute lymphoblastic leukemia patients who have favorable prognosis, an attempt to reduce the burden of chemotherapy by using lower intensity delayed intensification failed to show better outcomes.
Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in a recently published phase I/II study.
The 5-year survival rate for relapsed/refractory acute lymphoblastic leukemia has been below 10%. Immunotherapies, however, are starting to challenge that paradigm.
Many adolescent girls with leukemia did not receive pregnancy screening before undergoing teratogenic exposure.
Maintenance therapy with TKIs following allogeneic HSCT is feasible and may improve outcomes in patients with high-risk Philadelphia chromosome–positive leukemia.
New research has shown that a higher dose of CTL019 with split dosing was associated with reduced toxicity in adult patients with relapsed, refractory CD19-positive ALL.